Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2008
06/19/2008WO2008071976A1 8-oxoadenine derivatives as immuno-modulators
06/19/2008WO2008071974A2 Use of pi3k m-tor and akt inhibitors to induce f0xp3 expression and generate regulatory t cells
06/19/2008WO2008071968A1 Cucurbitacin b and uses thereof
06/19/2008WO2008071966A2 Pharmaceutical composition of zolpidem
06/19/2008WO2008071964A1 Naphthyridine bactericides
06/19/2008WO2008071962A1 Pteridines and pyrimidinopyridines as antibacterial agents
06/19/2008WO2008071961A1 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
06/19/2008WO2008071960A2 Methods of increasing neurogenesis
06/19/2008WO2008071948A2 Aminoalcohol derivatives and their therapeutic use
06/19/2008WO2008071944A1 Benzoxazoles useful in the treatment of inflammation
06/19/2008WO2008071934A1 Treatment of cachexia
06/19/2008WO2008071931A1 Piperidine derivative used for treating chemokine receptor 5 mediated diseases
06/19/2008WO2008071927A1 Piperidine derivative used for treating chemokine receptor 5 mediated diseases
06/19/2008WO2008071851A1 Polyvalent bioconjugates
06/19/2008WO2008071803A1 Nutritional supplement composition for treatment of ocular diseases
06/19/2008WO2008071779A1 V3 antagonists for the treatment or prevention of chronic pain
06/19/2008WO2008071775A1 Nutritional supplement composition for treatment of ocular diseases
06/19/2008WO2008071765A1 Pharmaceutically active spiro-substituted benzimidazole derivatives
06/19/2008WO2008071736A1 Benzamide derivatives as ep4 receptor agonists
06/19/2008WO2008071665A1 A nicotinamide derivative useful as p38 kinase inhibitor
06/19/2008WO2008071664A1 Nicotinamide derivative used as a p38 kinase inhibitor
06/19/2008WO2008071646A1 New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds
06/19/2008WO2008071605A2 Methods of treating inflammatory diseases
06/19/2008WO2008071574A1 Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
06/19/2008WO2008071573A2 Powder formulation for valganciclovir
06/19/2008WO2008071528A1 Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops
06/19/2008WO2008071524A1 Use of l-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases
06/19/2008WO2008071456A2 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
06/19/2008WO2008071455A1 Bicyclic acyltryptophanols
06/19/2008WO2008071453A1 1,2-diarylacetylene derivatives of acyltryptophanols
06/19/2008WO2008071451A1 Dihydropyridine derivatives useful as protein kinase inhibitors
06/19/2008WO2008071421A1 Nitrate esters of carbonic anhydrase inhibitors
06/19/2008WO2008071416A1 Morin, a new inhibitor of microbial hyaluronate lyase
06/19/2008WO2008071404A1 Epothilone analogues modified at positions c12-c13 as anticancer drugs
06/19/2008WO2008071398A1 Sulfonamides and their use as a medicament
06/19/2008WO2008071397A1 Aromatic 1,4-di-carboxylamides and their use
06/19/2008WO2008071387A1 Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers
06/19/2008WO2008071359A1 Substituted aminofuranones and their use
06/19/2008WO2008071311A1 Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
06/19/2008WO2008071288A1 Indolizine derivatives and their use as antidiabetics
06/19/2008WO2008071245A1 Pharmaceutical preparation for the treatment of inflammatory diseases of the urogenital tract
06/19/2008WO2008071242A1 Method for inducing tumor apoptosis by increasing nitric oxide levels
06/19/2008WO2008071197A1 Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
06/19/2008WO2008071173A1 Preparations for inhibiting prostaglandin e2 synthesis
06/19/2008WO2008071058A1 Mercapto-group modified macromolecule derivative and cross-linked material
06/19/2008WO2008071010A1 Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
06/19/2008WO2008071009A1 Novel ligand guided block copolymers for targeted drug delivery
06/19/2008WO2008070996A1 Medical implants with a combination of compounds
06/19/2008WO2008070995A1 Methods and treatments for prevention of acute renal failure following cardiac surgery
06/19/2008WO2008070994A1 Use of d-serine derivatives for the treatment of anxiety disorders
06/19/2008WO2008070960A1 Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
06/19/2008WO2008070950A1 Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
06/19/2008WO2008070940A1 Process of obtainment of soy isoflavones
06/19/2008WO2008070908A1 Chemical compounds and processes
06/19/2008WO2008070902A1 Tgf-beta compositions for treating infertility
06/19/2008WO2008055022A3 Carbamate compounds for use in treating depression
06/19/2008WO2008054796A3 Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
06/19/2008WO2008054795A3 Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
06/19/2008WO2008054698A3 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
06/19/2008WO2008053487A3 Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
06/19/2008WO2008052078A3 Benzoxathiine and benzoxathiole derivatives and uses thereof
06/19/2008WO2008052075A3 Benzoxazine derivatives and uses thereof
06/19/2008WO2008051875A3 Adamantylurea compounds as soluble epoxide hydrolase inhibitors
06/19/2008WO2008051873A3 Phenylurea compounds as soluble epoxide hydrolase inhibitors
06/19/2008WO2008051862A3 Immunopotentiating compositions comprising beta-1,3/1,6-d-glucan and uses thereof
06/19/2008WO2008051794A3 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
06/19/2008WO2008051793A3 Method of preventing or treating metabolic syndrome
06/19/2008WO2008051564A3 Crystalline forms of palonosetron hydrochloride
06/19/2008WO2008051531A3 Discontinuous methods of treating cancer
06/19/2008WO2008050339A9 Combination of an aminoglycoside antibiotic and a parp inhibitor
06/19/2008WO2008049996A3 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
06/19/2008WO2008049984A3 Use of citrulline for treating undernutrition conditions
06/19/2008WO2008049974A8 Peptide vaccine for influenza virus
06/19/2008WO2008049516A3 Transdermal therapeutic system comprising norelgestromin for contraception and hormone replacement
06/19/2008WO2008049123A3 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
06/19/2008WO2008049043A3 Ophthalmic compositions comprising diglycine
06/19/2008WO2008049042A3 Ophthalmic compositions containing diglycine
06/19/2008WO2008047320A3 Multiple unit tablet compositions of benzimidazole compounds
06/19/2008WO2008046994A3 Novel composition and uses thereof, in particular cosmetic uses, for treating skin dehydration
06/19/2008WO2008046982A3 New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7
06/19/2008WO2008046606A3 Topical composition for the treatment of eczema
06/19/2008WO2008046082A3 Use of heterocyclic compounds as therapeutic agents
06/19/2008WO2008045852A3 Purification of streptococcus pneumoniae type 3 polysaccharides
06/19/2008WO2008045566B1 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
06/19/2008WO2008045535A3 Convertible nucleoside derivatives
06/19/2008WO2008045371A3 N-substituted-azacyclylamines as histamine-3 antagonists
06/19/2008WO2008044027A3 Pharmaceutical compounds having hsp90 inhibitory or modulating activity
06/19/2008WO2008043544A8 Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
06/19/2008WO2008041134A3 Use of chlorine guanabenz derivatives for treating prion-based diseases
06/19/2008WO2008039052A3 Process for stabilizing famotidine
06/19/2008WO2008038051A3 Use of ion channel modulators in the prophylaxis and treatment of inflammatory and immunological diseases
06/19/2008WO2008036400A3 Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome
06/19/2008WO2008035207A3 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
06/19/2008WO2008035204A3 Prediction and prophylactic treatment of type 1 diabetes
06/19/2008WO2008034202A3 Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis
06/19/2008WO2008033543A9 Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment
06/19/2008WO2008033300A8 Bis (thiohydrazide amides) formulation
06/19/2008WO2008031439A3 Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol
06/19/2008WO2008030373A3 L- oddc prodrugs for cancer
06/19/2008WO2008028965A3 Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
1 ... 3212 3213 3214 3215 3216 3217 3218 3219 3220 3221 3222 3223 3224 3225 3226 3227 3228 3229 3230 3231 3232 ... 7860